• Genvor posted a net loss of $429,567 for the three months ended March 31, 2026, widening 43.68%, with loss per share steady at ($0.01).
• Operating loss widened to $407,492, on operating expenses of $407,492, up from $276,056.
• Professional fees climbed to $55,778, up 559.16%, while compensation and related benefits rose to $253,361, up 33.8%.
• Cash totaled $94,808 at March 31, 2026, with a working capital deficit of $891,095 and accumulated deficit of $27.2 million.
• After quarter-end, it struck a securities purchase agreement with Evergreen Capital Management for a convertible promissory note of up to $800,000, alongside warrants for up to 600,000 shares, and signed a non-binding MOU with Canlab International to develop about five peptide candidates in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genvor Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001903596-26-000213), on May 13, 2026, and is solely responsible for the information contained therein.